國立高雄大學圖資館 |

Language: English

Back

Targeted therapies for lung cancer

Salgia, Ravi.

Targeted therapies for lung cancer

Record Type:	Electronic resources : Monograph/item
Title/Author:	Targeted therapies for lung canceredited by Ravi Salgia.
other author:	Salgia, Ravi.
Published:	Cham :Springer International Publishing :2019.
Description:	ix, 238 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	LungsCancer
Online resource:	https://doi.org/10.1007/978-3-030-17832-1
ISBN:	9783030178321$q(electronic bk.)

Targeted therapies for lung cancer
Targeted therapies for lung cancer[electronic resource] /edited by Ravi Salgia. - Cham :Springer International Publishing :2019. - ix, 238 p. :ill., digital ;24 cm. - Current cancer research,2199-2584. - Current cancer research..

1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

ISBN: 9783030178321$q(electronic bk.)

Standard No.: 10.1007/978-3-030-17832-1doiSubjects--Topical Terms:

531376
Lungs
--Cancer

LC Class. No.: RC280.L8 / T37 2019

Dewey Class. No.: 616.9942406

Targeted therapies for lung cancer
LDR:02416nmm a2200337 a 4500 001 563066
003 DE-He213
005 20190626000236.0
006 m d
007 cr nn 008maaau
008 200227s2019 gw s 0 eng d
020 $a 9783030178321$q(electronic bk.)
020 $a 9783030178314$q(paper)
024 7 $a 10.1007/978-3-030-17832-1 $2 doi
035 $a 978-3-030-17832-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8 $b T37 2019
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.9942406 $2 23
090 $a RC280.L8 $b T185 2019
245 1 0 $a Targeted therapies for lung cancer $h [electronic resource] / $c edited by Ravi Salgia.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a ix, 238 p. : $b ill., digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2584
505 0 $a 1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.
520 $a This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient's genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
650 0 $a Lungs $x Cancer $x Treatment. $3 531376
650 0 $a Drug targeting. $3 194481
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Molecular Medicine. $3 273932
700 1 $a Salgia, Ravi. $3 848439
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Current cancer research. $3 558904
856 4 0 $u https://doi.org/10.1007/978-3-030-17832-1
950 $a Medicine (Springer-11650)